Ventris® was started on the premise that our industry of products had room for improvement. Simply put, we want to raise the bar of excellence to provide solutions that are better than what is currently available.
Ventris® was started on the premise that our industry of products had room for improvement. Simply put, we want to raise the bar of excellence to provide solutions that are better than what is currently available.
Why Ventris® Matters
It’s our focus on quality, innovative design, and processing that sets Ventris® apart from the competition. Ventris® controls the supply chain – from the origin of the material all the way through to its clinical application.
Ventris® offers a broad variety of allograft, synthetic, and bioactive products for soft and hard tissue applications. We design, develop, and market best in class products for optimal surgical outcomes and level of patient care.
Our line of human allograft products is regulated by the FDA Center for Biologics Evaluation and Research (CBER), which regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps). Ventris® adheres to Current Good Tissue Practices, focusing extensively on donor eligibility and the recovery process. Ventris® Allograft products are regulated under 21 CFR Part 1270 and 21 CFR Part 1271 and Section 361 of the Public Health Services Act. The company is dedicated to providing products that adhere to the strictest current tissue banking and processing standards, with the ultimate goal of an exceptional outcome for the patient.
Russell Cook, Founder & CEO
Mr. Cook is a well-established entrepreneur with over 17 years of experience establishing and developing companies in the field of biologics. Cook founded Summit Surgical in 2002 and shortly after, founded Radius Medical in 2004. After the successful commercialization of a unique, novel bone graft material, Radius was acquired by NuVasive in 2007. In 2009, Cook founded his next venture, BioStructures. By 2015 BioStructures had five novel biologic products on the market and was acquired by Bioventus in November of that same year. Cook has a B.S. in Marketing from California State University with his postgraduate training at Columbia Business School in New York. With a deep understanding of sales, distribution, and product development activities that make a successful medical start-up, Cook has made a positive impact on the overall healthcare and biologics landscape. Cook’s guiding business philosophy, incorporating subject matter expertise with the unique needs of the marketplace, has been instrumental in not only the inception of a multitude of prosperous enterprises, but also in his development of opportune inventions. He has been granted four patents for unique bone graft substitutes, materials, and methods and continues to work on the development of additional products in the healthcare space.
Our Team
